ClinicalTrials.gg
RecruitingNCT07158489ORIGIN2Updated Oct 28, 2026

Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

A Phase 2 interventional study of Gemcitabine + Ivonescimab in NSCLC and NSCLC (Advanced Non-small Cell Lung Cancer), sponsored by Swiss Cancer Institute. Recruiting at 8 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Swiss Cancer Institute · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 28, 20262 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 5 under way, none of them phase 3. Gemcitabine · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
93rd of 152
47 · median 53
Started
2026
the only one that year
Phase 2
109 of 169
4 open now
Registered
169th of 169
by date

Among the 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung, this one is the 93rd largest by planned enrollment of the 152 interventional ones that give a count, is the only one that started in 2026, is one of 109 in phase 2, and was the 169th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

4 of the 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This Phase II clinical trial (investigates the efficacy of combining gemcitabine, a chemotherapy agent, with ivonescimab, a bispecific PD-1/VEGF antibody, in patients with advanced non-small cell lung cancer (NSCLC) who have experienced disease progression following chemoimmunotherapy (CIT). Lung cancer remains the leading cause of cancer-related death globally, and treatment options after CIT failure are limited. Gemcitabine has demonstrated immunostimulatory properties, including enhanced T-cell infiltration and reduced immunosuppressive cell populations, which may synergize with immune checkpoint inhibitors. Ivonescimab targets both PD-1 and VEGF pathways, potentially enhancing antitumor immune responses and inhibiting tumor angiogenesis. The trial aims to evaluate the objective response rate (ORR) according to RECIST v1.1 criteria. The combination therapy is expected to offer a novel and effective treatment strategy for patients with relapsed NSCLC, addressing a significant unmet medical need.

Read the detailed description

Lung cancer is the most frequently diagnosed cancer worldwide, with approximately 2.5 million new cases and 1.8 million deaths annually. Most cases are diagnosed at an advanced stage, necessitating systemic therapy. Although chemoimmunotherapy (CIT) has improved outcomes, disease progression remains inevitable, and second-line treatments offer limited efficacy. Gemcitabine, a cytidine analogue, interferes with DNA synthesis and exhibits immunomodulatory effects, including increased effector T-cell infiltration and reduced regulatory T-cell activity. Preclinical studies have shown that gemcitabine enhances antitumor immune responses when combined with immune checkpoint inhibitors (ICIs), such as anti-PD-1 antibodies.

Ivonescimab (AK112/SMT112) is a bispecific antibody targeting PD-1 and VEGF, designed to simultaneously modulate immune and angiogenic pathways. It binds to PD-1 on activated T cells and VEGF involved in tumor angiogenesis. The combination of gemcitabine and ivonescimab is hypothesized to synergistically improve antitumor activity in patients with advanced NSCLC who have progressed after CIT.

Preclinical evidence from mouse models of mesothelioma demonstrated that combining gemcitabine with immunotherapy significantly increased survival and lymphocyte infiltration at the tumor site. This effect was negated by dexamethasone, highlighting the importance of immune modulation. Clinical observations in mesothelioma patients further support the potential of this combination.

Gemcitabine is a standard of care (SoC) for several solid tumors, including NSCLC. Its immunostimulatory properties make it a suitable candidate for combination with ICIs. Ivonescimab has shown superior efficacy compared to pembrolizumab in PD-L1+ NSCLC patients in first-line settings. Despite ongoing trials exploring similar combinations, none have investigated gemcitabine with ivonescimab.

This Phase II trial aims to assess the antitumor activity of gemcitabine combined with ivonescimab in patients with advanced NSCLC who have limited therapeutic options. Gemcitabine will be administered according to standard treatment recommendations, while ivonescimab will be given at 20 mg/kg every three weeks (q3w), consistent with previous trials.

The primary objective is to evaluate the objective response rate (ORR) based on RECIST v1.1 criteria, with independent response review. The study is inclusive across sex, gender, and ethnicity, and all materials will use gender-inclusive language. A positive outcome may support the adoption of this combination as a new standard treatment for relapsed NSCLC.

03

Conditions studied

  • NSCLC
  • NSCLC (Advanced Non-small Cell Lung Cancer)

Keywords

  • advanced NSCLC
  • immune checkpoint inhibitors
  • Resistance to immunotherapy
  • Gemcitabine and Ivonescimab
  • Gemcitabine
  • Ivonescimab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients fulfilling all of the following inclusion criteria are eligible for the trial:
  • Written according to Swiss law and ICH GCP E6 regulations before registration and prior to any trial specific procedures including patient screening.
  • Confirmed squamous or non-squamous mNSCLC stage IIIB-IV (based on 9th edition Tumor-Node- (TNM) classification of lung cancers with disease recurrence or progression during or after one or more prior immunotherapy or CIT regimens for metastatic disease.
  • Patients with treated and stable central nervous system (CNS) metastases are eligible, if:

    • Previous CNS-directed therapy has been completed at least 4 weeks prior to treatment start.
    • No evidence of progression after completion of CNS-directed therapy as ascertained by clinical examination and brain imaging with Magnetic Resonance Imaging (MRI) or CT.25
  • Patients with known -infection are eligible, if:

    • are ≥ 350 cells/µl
    • No history of AIDS-defining opportunistic infection within past 12 months
    • Patient agrees to concomitant antiretroviral therapy (ART) if not currently on ART, or is on ART for ˃ 4 weeks and has a HIV viral load ˂ 400 copies/ml.26
  • Patients with a previously treated are eligible if this is clinically stable and does not require concurrent tumor-directed treatment.

Exception: patients suffering from prostate cancer under hormonal ablation therapy (hormone sensitive disease).

  • Patients with according to v1.1.
  • Availability of newly collected or archival (maximum 3 months) samples for TR prior to treatment initiation.
  • Age ≥ 18 years
  • performance status 0-2.
  • Adequate bone marrow function: ≥ 1.5 x 109/l, count ≥ 100 x 109/l, ≥ 90 g/l.

6.1.11 Adequate hepatic function: total ≤ 1.5 x ([ULN]; except for patients with Gilbert's disease ≤ 3.0 x ULN), (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN, or ≤ 5 x ULN for patients with hepatic metastasis.

  • Adequate renal function: estimated (eGFR) ≥ 40 ml/min/1.73 m2 (according to the Chronic Kidney Disease Epidemiology Collaboration) abbreviated formula CKD-EPI formula.
  • Women of , including women who had their last menstrual period in the last 2 years, must use highly effective , are not pregnant or lactating and agree not to become pregnant during trial treatment and until 6 months after the last dose of drug . A negative serum or urine pregnancy test before starting trial treatment is required for all women of childbearing potential.
  • Men agree not to donate sperm or father a child during trial treatment and until 6 months after the last administration of investigational drug.
  • Patients give their consent to participate in TR projects and providing the mandatory samples.

Exclusion criteria

Exclusion Criteria:

  • Symptomatic .
  • Prior treatment with gemcitabine in combination with immunotherapies.
  • Tumor progression within the first 8 weeks from start of treatment.
  • Activating EGFR or ALK mutations.
  • Concomitant use of other anti-cancer drugs or radiotherapy.
  • Major surgery within 1 month prior to treatment start.
  • Known history of any uncontrolled active systemic infection requiring intravenous antimicrobial treatment.
  • Known history of tuberculosis, primary immunodeficiency, allogeneic tissue/solid organ transplant, or receipt of .
  • History of interstitial lung disease or severe pneumonitis.
  • Concomitant use of as premedication for gemcitabine therapy.
  • Concomitant or prior use of medication such as interferon or methotrexate within 28 days prior to trial treatment start, with the exceptions of local (i.e., intranasal, inhaled and topical) corticosteroids.
  • Major blood vessel tumor invasion.
  • Minor local procedures (excluding central venous catheterization and port implantation) within 3 days prior to study treatment initiation.
  • Unstable angina, myocardial infarction, congestive heart failure ( classification Grade ≥2;27) or vascular disease (e.g., aortic aneurysm at risk of rupture) that required hospitalization within 12 months prior to study treatment initiation, or other cardiac impairment that may affect the safety evaluation of the study drug (e.g., poorly controlled arrhythmias, myocardial ischemia).
  • History of esophageal gastric varices, severe ulcers, wounds that do not heal, abdominal fistula, intra-abdominal abscesses, or acute gastrointestinal bleeding within 6 months prior to study treatment initiation.
  • History of arterial thromboembolic event, venous thromboembolic event of Grade ≥3 as specified in v5.0, , cerebrovascular accident, hypertensive crisis, or hypertensive encephalopathy within 6 months prior to study treatment initiation.
  • Acute exacerbation of within 4 weeks prior to study treatment initiation.
  • History of perforation of the gastrointestinal tract and/or fistula, history of gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive bowel resection (partial colectomy or extensive small bowel resection) within 6 months prior to study treatment initiation.
  • Any concomitant drugs for use with the trial drugs according to the approved product information or to the Investigator's Brochure (IB).
  • Known or suspected to gemcitabine or ivonescimab or to any component of the trial drugs.
  • History of bleeding tendencies or coagulopathy and/or bleeding symptoms or risk within 4 weeks prior to registration, including but not limited to:

    • Hemoptysis (defined as coughing up ≥ 0.5 teaspoon of fresh blood or small blood clots).

Note: transient hemoptysis associated with diagnostic bronchoscopy is allowed.

  • Nasal bleeding /epistaxis (bloody nasal discharge is allowed).
  • Current use of prophylactic or full-dose anticoagulants or anti- agents for therapeutic purposes that is not stable prior to registration is not allowed. The use of full-dose anticoagulants is permitted as long as the (INR) or activated partial thromboplastin time is within therapeutic limits according to the medical standard of the enrolling institution.

    • Poorly controlled hypertension with repeated systolic blood pressure ≥ 150 mmHg or diastolic pressure ≥ 100 mmHg after oral antihypertensive therapy.
    • Active or lung disease requiring systemic therapy (e.g., with disease modifying drugs, prednisone >10 mg daily or equivalent, immunosuppressant therapy) within 2 years prior to registration, however the following will be allowed:
  • Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is permitted.
  • Intermittent use of bronchodilators, inhaled corticosteroids, or local corticosteroid injections is permitted.

    • Has pre-existing peripheral neuropathy that is ≥ Grade 2 by NCI CTCAE v5.0.
    • Uncontrolled pleural effusions, pericardial effusions, or ascites that is clinically symptomatic.

Note: Patients managed with indwelling catheters (e.g., PleurX) are allowed.

  • History of non-infectious pneumonia requiring systemic corticosteroids, or current interstitial lung disease.
  • Active or prior history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea).
  • Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (estimated)

Study arms

  • Experimental
    Gemcitabine + Ivonescimab in Advanced NSCLC Resistant to Immunotherapy

    Drug: Gemcitabine + Ivonescimab

Interventions

  • DrugGemcitabine + Ivonescimab

    Drug pages: GemcitabineStudies of GemcitabineGemcitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · IvonescimabStudies of IvonescimabIvonescimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The trial combines two Investigational Medicinal Products (IMPs): * Gemcitabine, either alone or in combination regimens, is the standard of care (SoC) for several solid tumors, such as advanced or metastatic non-small cell lung cancer (mNSCLC). * Ivonescimab is developed for cancer immunotherapy. Ivonescimab binds to human vascular endothelial growth factor (VEGF) which is involved in tumor angiogenesis, and to human programmed cell death 1 (PD-1) that is a cell surface receptor expressed primarily on activated T cells and acts to inhibit their activation.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) according to RECIST v1.1

    ORR according to RECIST v1.1 is defined as the proportion of patients, whose best overall response is either complete response (CR) or partial response (PR) achieved before disease progression according to RECIST v1.1 or start of a subsequent anti-cancer treatment whichever occurs first. Patients with CR or PR as best observed response will be considered as success; otherwise as failures for this endpoint. Patients without any tumor assessment or with non-evaluable response (NE) during trial treatment will be considered as failures for this endpoint. The primary analysis will be based on the results from the Independent Response Review.

    Time frame: At the end of trial treatment, up to 2 years from registration.

Secondary outcomes

  1. Duration of response (DoR) according to RECIST v1.1

    DoR according to RECIST v1.1 is defined as the time from the first documentation of CR or PR (whichever occurs first) until disease progression according to RECIST v1.1 or death due to any cause. Patients not experiencing an event at the time of analysis and those starting a subsequent anticancer treatment without an event will be censored at the date of their last available tumor assessment before starting subsequent anti-cancer treatment, if any. This endpoint will be calculated for the subgroup of patients achieving CR or PR. The analysis of this endpoint will be based on the independent response review.

    Time frame: From first response up to 2 years from treatment start.

  2. Progression-free Survival (PFS) according to RECIST v1.1

    PFS according to RECIST v1.1 is measured as the time from the first dose of ivonescimab/gemcitabine until disease progression according to RECIST v1.1 or death due to any cause. Patients not experiencing an event at the time of analysis and those receiving a subsequent anti-cancer treatment without an event will be censored at the date of their last available tumor assessment before starting subsequent anti-cancer treatment, if any. The analysis of this endpoint will be based on the independent response review.

    Time frame: From first dose of ivonescimab/gemcitabine, up to 2 years from treatment start.

07

Study locations

8 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jul 2028, 23 months after the start.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 23 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2025
First posted
Sep 5, 2025
StartActual
Aug 21, 2026
Primary completionEst.
Jul 2028
CompletionEst.
Jul 31, 2029
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed
Show 2 added (2 Switzerland)
  • HOCH Health Ostschweiz - Kantonsspital St. Gallen · Sankt Gallen, Switzerland
  • Spital STS AG · Thun, Switzerland
Show 1 removed
  • IOSI Ospedale Regionale di Bellinzona e Valli · Bellinzona, Switzerland
Oct 28, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Kantonsspital Baden · Baden, SwitzerlandContact c•••@ksb.ch · •••2762→s•••@ksb.ch · •••2762Contact person changed (no phone or email listed)
  • Universitätsspital Basel · Basel, SwitzerlandContact a•••@usb.ch · •••5074→c•••@usb.ch · •••5074Contact person changed (no phone or email listed)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    2 sites added, 1 site removed
    Show 2 added (2 Switzerland)
    • HOCH Health Ostschweiz - Kantonsspital St. Gallen · Sankt Gallen, Switzerland
    • Spital STS AG · Thun, Switzerland
    Show 1 removed
    • IOSI Ospedale Regionale di Bellinzona e Valli · Bellinzona, Switzerland
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Kantonsspital Baden · Baden, SwitzerlandContact c•••@ksb.ch · •••2762→s•••@ksb.ch · •••2762Contact person changed (no phone or email listed)
    • Universitätsspital Basel · Basel, SwitzerlandContact a•••@usb.ch · •••5074→c•••@usb.ch · •••5074Contact person changed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07158489
Lead sponsor
Swiss Cancer Institute
Responsible party
Sponsor
First posted
Sep 5, 2025
Start date
Aug 21, 2026
Primary completion
Jul 2028 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Oct 28, 2026

Study contacts

Jana Musilova, PhD
Contact
trials@swisscancerinstitute.ch
031 389 91 91 ext. +41
Alessandra Curioni-Fontecedro, Prof
study chair · Cantonal Hospital Fribourg / University of Fribourg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Ivonescimab

Start the discussion